Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 3,022 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Mechlorethamine Clear all

Conditions: Core Binding Factor Alpha Subunits, Hematologic Neoplasms, Leukemia, Lymphoma
Interventions: Cyclophosphamide, Busulfan, Fludarabine, Total Body Irradiation, Hematopoietic stem cells, Tacrolimus, Mycophenolate Mofetil; Drug · Radiation · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 4 Years to 70 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma
Interventions: cyclophosphamide, Mature dendritic cell vaccine; Drug · Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hodgkin Disease
Interventions: Doxorubicin, Vinblastine, Cyclophosphamide, Etoposide, Vincristine, Bleomycin, Gemcitabine, Vinorelbine, Prednisone; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Stanford, California

Conditions: Non-Hodgkin's Lymphoma
Interventions: Obinutuzumab, Bendamustine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 33
States / cities: Mobile, Alabama • Casa Grande, Arizona • Rogers, Arkansas + 26 more

Conditions: Breast Cancer
Interventions: therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy; Biological · Drug · Genetic + 3 more
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Tampa, Florida • Omaha, Nebraska

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Avelumab, Utomilumab, Rituximab, Azacitidine, Bendamustine, Gemcitabine, Oxaliplatin; Biological · Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 9
States / cities: Duarte, California • Louisville, Kentucky • New Orleans, Louisiana + 4 more

Conditions: Multiple Myeloma
Interventions: M-VTD-PACE, TT3-LITE Regimen (L-TT3); Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2028
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Interventions: Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 18
States / cities: Tucson, Arizona • Encinitas, California • La Jolla, California + 15 more

Conditions: Splenomegaly, Myelofibrosis
Interventions: Ruxolitinib, Allogeneic Stem Cell Transplantation, Levetiracetam, Eltrombopag, Busulfan, Romiplostim, Fludarabine phosphate, Cyclophosphamide, Mesna, Tacrolimus; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma
Interventions: aldesleukin, filgrastim, recombinant interferon alfa, busulfan, cyclophosphamide, cytarabine, doxorubicin hydrochloride, leucovorin calcium, methotrexate, prednisone, teniposide, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Azer-cel, Fludarabine, Cyclophosphamide, IL-2, Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib; Biological · Drug
Lead sponsor: Imugene Limited; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 10
States / cities: Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 6 more

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Cyclophosphamide, Fludarabine, Fludarabine Phosphate; Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
Interventions: arsenic trioxide, ascorbic acid, melphalan, chemosensitization/potentiation, chemotherapy; Drug · Procedure
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 19
States / cities: Glendale, Arizona • Bakersfield, California • Campbell, California + 16 more

Conditions: B-cell Lymphoma
Interventions: Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide; Biological · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 5
States / cities: Gilbert, Arizona • Duarte, California • Tampa, Florida + 2 more

Conditions: Multiple Myeloma, Plasma Cell Myeloma
Interventions: bortezomib, cisplatin, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, etoposide, lenalidomide, melphalan, thalidomide, gene expression analysis, microarray analysis, laboratory biomarker analysis, autologous-autologous tandem hematopoietic stem cell transplantation; Drug · Genetic · Other + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 21
States / cities: Alexandria, Louisiana • Baton Rouge, Louisiana • Detroit, Michigan + 12 more

Conditions: Squamous Cell Carcinoma of the Penis, Usual Type
Interventions: ILND - Inguinal Lymph Node Dissection, Paclitaxel, Ifosfamide, Cisplatin, Intensity modulated radiation treatment (IMRT), Prophylactic PLND - pelvic lymph node dissection; Procedure · Drug · Radiation
Lead sponsor: Institute of Cancer Research, United Kingdom; Other
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Lymphodepleting Chemotherapy, Myeloid Malignancies
Interventions: Cyclophosphamide, Fludarabine phosphate, Decitabine, Dexamethasone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ocular Melanoma, Uveal Melanoma
Interventions: Melphalan/HDS; Combination Product
Lead sponsor: Delcath Systems Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 9
States / cities: Tucson, Arizona • Palo Alto, California • Tampa, Florida + 6 more

Conditions: Graft-versus-Host Disease (GVHD), Hematologic Malignancies, Allogeneic Stem Cell Transplantation
Interventions: Cyclophosphamide (primary intervention for GVHD prophylaxis); Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Lymphoma
Interventions: rituximab, cyclophosphamide; Biological · Drug
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 3
States / cities: Newport Beach, California • Bloomington, Indiana • Bryan, Texas

Conditions: Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder, Bone Marrow Failure, Dyskeratosis Congenita, Telomere Biology Disorders
Interventions: Total Body Irradiation (TBI) (Plan 1), Cyclophosphamide (CY) (Plan 1), Fludarabine (FLU), Methylprednisolone (MP), Donor mobilized PBSC infusion, G-CSF, Cyclophosphamide (CY) (Plan 2), Rituximab, Busulfan, Alemtuzumab, Melphalan; Drug · Device
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Lymphoma, Hodgkin's Disease
Interventions: Melphalan, Ara-C, VP-16, BCNU, Rituxan, Stem Cells; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2017
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: fludarabine phosphate, melphalan, allogeneic hematopoietic stem cell transplantation, intensity-modulated radiation therapy; Drug · Procedure · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 7 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: MDS, Leukemias, Lymphomas
Interventions: Busulfan, Cyclophosphamide, Total body irradiation; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 6 Months to 65 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 2
States / cities: Baltimore, Maryland

Search by objective public record fields.

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma

Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention

Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease

Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies

Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy